Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider. You should consider whether you understand how spread bets and CFDs work, and whether you can afford to take the high risk of losing your money.
61% of retail CFD accounts lose money. Don’t invest unless you’re prepared to lose all the money you invest. This is a high-risk investment and you should not expect to be protected if something goes wrong. Take 2 mins to learn more at https://etoro.tw/44JRWLY
CFDs and FX are complex instruments and come with a high risk of losing money rapidly due to leverage. Between 74-89% of retail investor accounts lose money when trading CFDs. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider. You should consider whether you understand how spread bets and CFDs work, and whether you can afford to take the high risk of losing your money.
61% of retail CFD accounts lose money. Don’t invest unless you’re prepared to lose all the money you invest. This is a high-risk investment and you should not expect to be protected if something goes wrong. Take 2 mins to learn more at https://etoro.tw/44JRWLY
CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 74% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider. You should consider whether you understand how spread bets and CFDs work, and whether you can afford to take the high risk of losing your money.
61% of retail CFD accounts lose money. Don’t invest unless you’re prepared to lose all the money you invest. This is a high-risk investment and you should not expect to be protected if something goes wrong. Take 2 mins to learn more at https://etoro.tw/44JRWLY
CFDs and FX are complex instruments and come with a high risk of losing money rapidly due to leverage. Between 74-89% of retail investor accounts lose money when trading CFDs. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider. You should consider whether you understand how spread bets and CFDs work, and whether you can afford to take the high risk of losing your money.
61% of retail CFD accounts lose money. Don’t invest unless you’re prepared to lose all the money you invest. This is a high-risk investment and you should not expect to be protected if something goes wrong. Take 2 mins to learn more at https://etoro.tw/44JRWLY
CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 74% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
The Merus (NASDAQ: MRUS) stock price jumped over 30% in the early hours of the Thursday market open, after a conference call regarding positive data in multiple clinical trials.
Merus had positive data to report at today’s AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics – soon spurring the price rally that is still continuing at the time of writing – currently just over 34%.
The clinical-stage oncology company received positive results in the testing of both MCLA-158 – used for head and neck squamous cell carcinoma – and Zeno, used for reducing tumor growth in NRG1+ cancers; in Merus’ latest string of innovative, multispecific antibodies.
Sponsored content
Ready to put what you’ve learned into practice?
Try IG’s platform with £10,000 in virtual funds and practise trading
without putting your own money at risk.
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
Sponsored content
Learn the markets with IG Academy
Build your knowledge with IG Academy educational content, then use a
demo account to practise what you’ve learned on the IG platform.
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
Sponsored content
See how trading works before risking real money
IG’s demo gives you access to thousands of markets and £10,000 in
virtual funds, so you can explore the platform and test your ideas first.
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
Sponsored content
Turn trading theory into practical experience
Learn with IG Academy, explore charts and market tools, and practise
strategies in a simulated trading environment before going live.
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
Sponsored content
Ready to take your learning further?
IG combines market education, analysis and an established trading platform,
giving you the tools to keep learning as you develop your trading skills.
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
In MCLA-158 clinical data, tumor shrinkage was witnessed in patients with HNSCC. In preclinical trials, Zeno has been found to block cell growth ‘100 fold more potently’ than the previous anti-HER3 antibody.
Dr. Andrew Joe, Chief Medical Officer at Merus, confidently announced:
“We are encouraged by the early evidence of clinical activity of MCLA-158 in patients with advanced, previously treated HNSCC, further validating the potential of our Biclonics platform. With Zeno, our preclinical research continues to reinforce the mechanisms by which Zeno is capable of potently inhibiting the growth of NRG1 fusion cancers.”
Sponsored
Merus Daily Chart, Source: IG
The market reacted incredibly positively to the conference results, with the Merus stock price holding strongly onto gains of over 30%. Merus is currently trading at $27.4, on the path to approaching annual highs of $29.
Should You Invest in Merus Shares?
One of the most frequently asked questions we receive is, “what stocks are best to buy right now?” It’s a wide-ranging question, but one that we have answered… Our AskTraders stock analysts regularly review the market and compile a list of which companies you should be adding to your portfolio, including short and longer-term positions. Here are the best stocks to buy right now
Nigel has been in the regulated financial services industry for nearly a decade, has previously owned a financial brokerage and has written many times for sites relating to personal finance and trading.
Stay ahead of the markets
Sign up to our free Morning Markets email, every weekday before the open.
Stay ahead of the markets
Morning Markets
Weekdays
FTSE, overnight moves and what matters before the open.
Show personalised advertising and content, and measure how adverts and content perform
Learn about our audience and develop and improve our services
Learn more
Advertising pays for our free market news, analysis and trading tools.
If you accept, we and our partners may also match and combine data from other sources, link your devices, and identify your device from its characteristics, precise location or by actively scanning it. Some partners rely on legitimate interest rather than consent for certain purposes; you can object in the full list.
You can reject, or choose which purposes to allow under Manage options. Your choice is kept for this browser and you can change it at any time. See every purpose and partner
Necessary
Always active
Needed to run AskTraders and to remember your choice here. Always on.
Preferences
Remembers choices you make on AskTraders, such as display settings.
Analytics
Lets us count visits and see which pages are useful, using tools such as Google Analytics.The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Advertising and personalisation
Lets us and our advertising partners show personalised adverts and content, measure them and learn about our audience, and lets us offer web push notifications. See every purpose and partner
We and our advertising partners use cookies to show relevant advertising and measure its performance. You can opt out of the sale or sharing of your personal information, and of personalised advertising, at any time using the link below.
Necessary
Always active
Needed to run AskTraders and to remember your choice here. Always on.
Preferences
Remembers choices you make on AskTraders, such as display settings.
Analytics
Lets us count visits and see which pages are useful, using tools such as Google Analytics.The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Advertising and personalisation
Lets us and our advertising partners show personalised adverts and content, measure them and learn about our audience, and lets us offer web push notifications. See every purpose and partner
